A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma

Trial Profile

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Ilixadencel (Primary) ; Sorafenib
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Adverse reactions
  • Sponsors Immunicum
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 May 2018 According to Immunicum media release, company presented a case study of one patient from this trial at the Cholangiocarcinoma Foundation Annual Conference in Salt Lake City, Utah
    • 26 Sep 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top